Lexeo Therapeutics

Lexeo Therapeutics

Edit info

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Batten disease (ODD)
  • Drug types: GEN, NEU, CVV, RAR
  • Lead product: LX1004
  • Funding: $100M Sep 2021; $85M A Jan 2021


lexeotx.com

linkedin.com

job board


Business:

Gene Therapy

Drug notes:

LX2006 Clin1/Clin2 cardiac Friedreich's ataxia; LX1001 Clin1/Clin2 Alzheimer's; LX2020 Clin0 arrhythmogenic cardiomyopathy; LX1021 RD Alzheimer's; LX2021 RD arrhythmogenic cardiomyopathy; LX2022 RD hypertrophic cardiomyopathy; LX1020 Clin0 Alzheimer's

About:

Lexeo Therapeutics is creating high-impact genetic medicines for cardiovascular diseases and APOE4-associated Alzheimer’s disease. Cardiovascular disease remains the most significant cause of morbidity and mortality in the western world and rapidly becoming a primary cause worldwide. Lexeo is developing a number of disease-modifying gene therapy candidates to treat larger-rare cardiovascular diseases. In addition, Lexeo is using their same gene therapy technology to build a pipeline of central-nervous system (CNS) focused therapies. In both the cardiac and CNS programs Lexeo is advancing their pipeline into clinical trials.

Lexeo Therapeutics
Senior Clinical Trial Associate
New York, NY|26 days ago
Apply
Lexeo Therapeutics
Director/Senior Director, Clinical Statistician
New York, NY|96 days ago
Lexeo Therapeutics
Director, Clinical Scientist, Gene Therapy
New York, NY|98 days ago


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com